Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma

Abstract Background Immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combinations are a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC). Their efficacy and toxicity beyond the first‐line setting remain poorly defined. Methods We retrospectively...

Full description

Bibliographic Details
Main Authors: Yuanquan Yang, Sarah P. Psutka, Anish B. Parikh, Mingjia Li, Katharine Collier, Abdul Miah, Sherry V. Mori, Megan Hinkley, Scott S. Tykodi, Evan Hall, John A. Thompson, Ming Yin
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:Cancer Medicine
Subjects:
immune checkpoint inhibitor
immunotherapy
renal cell carcinoma
retrospective review
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/cam4.4679

Internet

https://doi.org/10.1002/cam4.4679

Similar Items